The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
ALPHA3: A pivotal phase 2 study of first-line (1L) consolidation with cemacabtagene ansegedleucel (cema-cel) in patients (pts) with large B-cell lymphoma (LBCL) and minimal residual disease (MRD) after response to standard therapy.
 
Jason Westin
Consulting or Advisory Role - Abbvie; Abbvie; ADC Therapeutics; Allogene Therapeutics; AstraZeneca; Bristol-Myers Squibb/Celgene/Juno; Chugai Pharma; Genentech/Roche; Genmab; Janssen Scientific Affairs; Kite/Gilead; MorphoSys/Incyte; Novartis; Nurix; Regeneron; Seagen
Research Funding - ADC Therapeutics; Allogene Therapeutics; AstraZeneca; Bristol-Myers Squibb; Genentech/Roche; Janssen; Kite/Gilead; MorphoSys/Incyte; Novartis
 
Gary Simmons
Speakers' Bureau - Kite, a Gilead company
 
Nancy Bartlett
Consulting or Advisory Role - Foresight Diagnostics; Genmab/AbbVie; Kite, a Gilead company; Pfizer/SeaGen; Roche/Genentech
Research Funding - ADC Therapeutics (Inst); Autolus (Inst); Bristol-Myers Squibb/Celgene (Inst); Forty Seven (Inst); Genmab/Abbvie (Inst); Janssen (Inst); Kite, a Gilead company (Inst); Millennium (Inst); Pharmacyclics (Inst); Roche/Genentech (Inst); Seagen (Inst)
 
Houston Holmes
Leadership - Exuma Biotech
Research Funding - ADC Therapeutics (Inst); Adicet Bio (Inst); Allogene Therapeutics (Inst); Artiva (Inst); Autolus (Inst); Bristol-Myers Squibb/Celgene (Inst); Caribou Biosciences (Inst); Celgene (Inst); Genentech (Inst); Incyte (Inst); Janssen (Inst); Juno Therapeutics (Inst); Kite, a Gilead company (Inst); MorphoSys (Inst); Novartis (Inst); Poseida Therapeutics (Inst); Precision Biosciences (Inst); Viracta Therapeutics (Inst)
 
Matthew Matasar
Stock and Other Ownership Interests - Merck
Honoraria - ADC Therapeutics; Bayer; Bristol-Myers Squibb/Celgene/Juno; Epizyme; Genentech; GlaxoSmithKline; Immunovaccine; Janssen; Pharmacyclics; Roche; Seagen; Takeda
Consulting or Advisory Role - Arvinas; Bayer; Daiichi Sankyo; Epizyme; Genentech; Juno Therapeutics; Merck; Roche; Rocket Medical; Seagen; Takeda; Teva; Treeline Biosciences
Research Funding - Bayer; Genentech; GlaxoSmithKline; IGM Biosciences; IGM Biosciences; Immunovaccine; Janssen; Pharmacyclics; Roche; Rocket Medical; Seagen
Expert Testimony - Bayer
Travel, Accommodations, Expenses - Bayer; Genentech; Roche; Seagen
 
Habte Yimer
Speakers' Bureau - Abbvie; Amgen; BeiGene; G1 Therapeutics; Genmab; Janssen; Karyopharm Therapeutics; Pfizer
 
Mitul Gandhi
Honoraria - GlaxoSmithKline; Janssen Oncology; Janssen Oncology (Inst); Karyopharm Therapeutics; Sanofi; TG Therapeutics
 
Jeff Sharman
Employment - US Oncology Network
Honoraria - Research to Practice
Consulting or Advisory Role - Abbvie; AstraZeneca; BeiGene; Bristol-Myers Squibb; Genentech; Janssen Oncology; Lilly; Merck
 
Ran Reshef
Consulting or Advisory Role - Allogene Therapeutics; Autolus Therapeutics; Gilead Sciences; Incyte; Orca Bio; Quell Biotherapeutics; Sana Biotechnology; TScan Therapeutics
Research Funding - Abbvie (Inst); Atara Biotherapeutics (Inst); Bristol-Myers Squibb (Inst); Cabaletta Bio (Inst); CareDX (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); immatics (Inst); Incyte (Inst); Janssen (Inst); Precision Biosciences (Inst); Sanofi (Inst); Synthekine (Inst); Takeda (Inst); TCR2 Therapeutics (Inst); TScan Therapeutics (Inst)
Expert Testimony - Bayer
Travel, Accommodations, Expenses - Gilead Sciences; Janssen
 
Akil A Merchant
No Relationships to Disclose
 
Yuliya Linhares
Consulting or Advisory Role - ADC Therapeutics; AstraZeneca/Merck; BeiGene; Genentech; Gilead Sciences; GlaxoSmithKline; Kyowa Kirin International; Seagen
Speakers' Bureau - Kyowa Kirin International
Research Funding - BeiGene
 
Don Stevens
No Relationships to Disclose
 
Alex Herrera
Consulting or Advisory Role - Abbvie; ADC Therapeutics; Adicet Bio; Alimera Sciences; AstraZeneca/MedImmune; Bristol-Myers Squibb; Caribou Biosciences; Genentech/Roche; Genmab; Merck; Pfizer; Seagen; Takeda
Research Funding - ADC Therapeutics (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); Kite, a Gilead company (Inst); Merck (Inst); Seagen (Inst)
 
Frederick Locke
Consulting or Advisory Role - A2 Biotherapeutics; Alimera Sciences; Amgen; Bluebird Bio; Bristol-Myers Squibb; Bristol-Myers Squibb/Celgene; Calibr; Caribou Biosciences; Celgene; Cowen; Daiichi Sankyo/UCB Japan; EcoR1 Capital; Gerson Lehrman Group; Iovance Biotherapeutics; Janssen; Kite, a Gilead company; Legend Biotech; Miltenyi Biotec; Novartis; Sana Biotechnology; Takeda; Takeda; Umoja Biopharma
Research Funding - Alimera Sciences (Inst); Bluebird Bio (Inst); Bristol-Myers Squibb/Celgene (Inst); Kite, a Gilead company (Inst); Novartis (Inst)
Patents, Royalties, Other Intellectual Property - CAR T Cells with Enhanced Metabolic Fitness. Serial Number: 62/939,727 (Inst); Double Mutant Survivin Vaccine. US010414810B2. (Inst); Evolutionary Dynamics of Non-Hodgkin Lymphoma CAR-T cell therapy. Serial Number: 62/879,534. (Inst); Methods of Enhancing CAR T Cell Therapies. Serial Number: 62/892,292. (Inst)
Travel, Accommodations, Expenses - A2 Biotherapeutics; Kite, a Gilead company
 
Amy Feng
Employment - Allogene Therapeutics
Stock and Other Ownership Interests - Allogene Therapeutics
 
Lynn Navale
Employment - Allogene Therapeutics
Leadership - None
Stock and Other Ownership Interests - Gilead, Amgen, Sana, Allogene
Honoraria - None
Consulting or Advisory Role - None
Speakers' Bureau - None
Research Funding - None
Patents, Royalties, Other Intellectual Property - None
Expert Testimony - None
Travel, Accommodations, Expenses - Allogene Therapeutics
Other Relationship - None
(OPTIONAL) Uncompensated Relationships - None
 
Jennifer Tsai
Employment - Allogene Therapeutics; Roche
Stock and Other Ownership Interests - Roche
 
John Le Gall
Employment - Allogene Therapeutics; Instil Bio
Stock and Other Ownership Interests - Allogene Therapeutics; Instil Bio; Johnson & Johnson/Janssen
Patents, Royalties, Other Intellectual Property - TIL patents pending
(OPTIONAL) Uncompensated Relationships - CRM Nepal
 
John Burke
Consulting or Advisory Role - Abbvie; AstraZeneca; BeiGene; Bristol Myers Squibb; CRISPR Therapeutics; Genentech/Roche; Genmab; Lilly; Novartis; Regeneron; Seagen
Travel, Accommodations, Expenses - Genentech/Roche
 
ALPHA3 Investigators
No Relationships to Disclose